Sanjit Singh Analyst Performance

The Department of Justice recently argued in court that cash isn't property - a claim that could reshape how much control you actually have over the money in your bank account. If your balance isn't legally guaranteed to be yours, who really controls it? Three strategies may help you prepare before any restrictions take hold.

A NASDAQ-listed biotech just cleared a major regulatory milestone. The FDA has cleared its lead multiple sclerosis therapy, Lucid-MS, to enter Phase 2 clinical trials - the first time it will be tested in patients with progressive MS. Unlike treatments that suppress the immune system, Lucid-MS is designed to protect myelin, the insulating layer destroyed by the disease. In a pre-clinical mouse model, treatment led to movement recovery including walking. Independent research projects peak annual sales of up to $5 billion if Phase 2 succeeds. The stock still trades under $5 per share.